Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ICPTNASDAQ:LXRXNASDAQ:VNDANASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/ALXRXLexicon Pharmaceuticals$0.75+0.6%$0.65$0.28▼$2.45$271.12M16.70 million shs4.33 million shsVNDAVanda Pharmaceuticals$4.51-0.4%$4.37$3.81▼$6.37$265.77M0.66623,690 shs323,828 shsVSTMVerastem$4.93-5.0%$6.70$2.10▼$9.10$270.90M0.851.19 million shs7.28 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%0.00%LXRXLexicon Pharmaceuticals0.00%+11.69%+13.65%+105.25%-59.46%VNDAVanda Pharmaceuticals0.00%0.00%+4.16%-6.43%-26.31%VSTMVerastem0.00%-11.96%-40.67%-28.34%+56.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALXRXLexicon Pharmaceuticals2.6427 of 5 stars3.24.00.00.01.42.50.6VNDAVanda Pharmaceuticals4.5457 of 5 stars3.82.00.04.22.63.31.3VSTMVerastem2.1798 of 5 stars3.52.00.00.00.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICPTIntercept Pharmaceuticals 0.00N/AN/AN/ALXRXLexicon Pharmaceuticals 2.40Hold$3.67388.89% UpsideVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50265.85% UpsideVSTMVerastem 3.00Buy$13.63176.37% UpsideCurrent Analyst Ratings BreakdownLatest VNDA, LXRX, VSTM, and ICPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$13.005/13/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.005/7/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.004/1/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/24/2025VSTMVerastemGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $14.003/24/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICPTIntercept Pharmaceuticals$285.71M2.78N/AN/A$1.72 per share11.05LXRXLexicon Pharmaceuticals$31.08M8.72N/AN/A$0.40 per share1.88VNDAVanda Pharmaceuticals$198.77M1.34N/AN/A$9.24 per share0.49VSTMVerastem$10K27,090.35N/AN/A($0.65) per share-7.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICPTIntercept Pharmaceuticals$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/ALXRXLexicon Pharmaceuticals-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%7/30/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)VSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)Latest VNDA, LXRX, VSTM, and ICPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LXRXLexicon Pharmaceuticals-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/7/2025Q1 2025VNDAVanda Pharmaceuticals-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICPTIntercept Pharmaceuticals3.124.222.52LXRXLexicon Pharmaceuticals0.482.222.22VNDAVanda PharmaceuticalsN/A3.933.91VSTMVerastem2.773.503.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICPTIntercept Pharmaceuticals83.81%LXRXLexicon Pharmaceuticals74.70%VNDAVanda Pharmaceuticals88.14%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipICPTIntercept Pharmaceuticals6.20%LXRXLexicon Pharmaceuticals13.90%VNDAVanda Pharmaceuticals8.90%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableICPTIntercept Pharmaceuticals34141.83 million39.19 millionOptionableLXRXLexicon Pharmaceuticals140361.49 million311.25 millionOptionableVNDAVanda Pharmaceuticals29058.93 million53.69 millionOptionableVSTMVerastem5054.95 million53.80 millionOptionableVNDA, LXRX, VSTM, and ICPT HeadlinesRecent News About These CompaniesFinancial Contrast: Verastem (NASDAQ:VSTM) vs. Ensysce Biosciences (NASDAQ:ENSC)June 16, 2025 | americanbankingnews.comVerastem’s SWOT analysis: biotech stock poised for growth amid challengesJune 15, 2025 | investing.comVerastem reports promising cancer drug trial resultsJune 4, 2025 | investing.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 4, 2025 | businesswire.comVerastem’s Promising Clinical Advances and Strategic Developments Justify Buy RatingJune 3, 2025 | tipranks.comVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from BrokeragesJune 3, 2025 | marketbeat.comVerastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns BullishJune 2, 2025 | msn.comVerastem Announces Strategic Plans in Investor WebcastJune 2, 2025 | tipranks.comWhat's Going On With Verastem Oncology Stock On Monday?June 2, 2025 | benzinga.comVerastem, Inc. (NASDAQ:VSTM) Short Interest UpdateJune 2, 2025 | marketbeat.comVerastem Announces Promising Phase 1 Study ResultsJune 2, 2025 | tipranks.comVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) InhibitorJune 2, 2025 | businesswire.comInvestors Buy Large Volume of Verastem Call Options (NASDAQ:VSTM)May 31, 2025 | marketbeat.comVSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug ApprovalMay 28, 2025 | zacks.comVerastem Oncology to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | businesswire.comNorthern Trust Corp Boosts Holdings in Verastem, Inc. (NASDAQ:VSTM)May 28, 2025 | marketbeat.com723,806 Shares in Verastem, Inc. (NASDAQ:VSTM) Bought by Woodline Partners LPMay 27, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New $387,000 Investment in Verastem, Inc. (NASDAQ:VSTM)May 27, 2025 | marketbeat.comVerastem’s SWOT analysis: biotech firm’s stock poised for growth amid challengesMay 23, 2025 | investing.comVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline ...May 23, 2025 | finance.yahoo.comVerastem expands ambitions with strong pancreatic cancer data at ASCOMay 23, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNDA, LXRX, VSTM, and ICPT Company DescriptionsIntercept Pharmaceuticals NASDAQ:ICPTIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Lexicon Pharmaceuticals NASDAQ:LXRX$0.75 +0.00 (+0.60%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.74 -0.01 (-1.07%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Vanda Pharmaceuticals NASDAQ:VNDA$4.51 -0.02 (-0.44%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.54 +0.03 (+0.64%) As of 06/20/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Verastem NASDAQ:VSTM$4.93 -0.26 (-5.01%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.09 +0.16 (+3.33%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
